2022年6月23日，甘肅省隴南市中級人民法院裁定確認恆康醫療集團股份有限公司（證券代碼：002219.SZ）重整計劃執行完畢並終結重整程序，恆康醫療於2022年7月4日完成撤銷相關退市風險警示，股票簡稱由「*ST恆康」變為「恆康醫療」，這標誌着恆康醫療重整案獲得成功，「中國民營醫院第一股」實現重生。
On June 23, 2022, the Intermediate People's Court of Longnan City of Gansu Province ruled to confirm that the reorganization plan of Hengkang Medical Group Co., Ltd. (「Hengkang」, 002219.SZ) had been executed and close the reorganization proceedings. On July 4, 2002, Hengkang had its delisting risk warning removed, and its stock symbol was changed from 「* ST Hengkang」 to 「Hengkang Medical」, marking its successful reorganization and a turning around of 「the first private hospital going public in China」.
中倫協助產業投資人北京新里程健康產業集團有限公司（「新里程」）及其聯合的財務投資人成功重整投資恆康醫療，助力新里程成為恆康醫療控股股東，在代表投資人重整投資上市公司的業務領域再創佳績。
Zhong Lun assisted Beijing New Journey Healthcare Group Co., Ltd. (「New Journey」) and other joint financial investors of Hengkang in investing in the reorganization and helped New Journey acquire the controlling interest in Hengkang. This mandate further consolidates Zhong Lun’s strong record in representing investors in reorganization investment in listed companies.
恆康醫療主營業務以醫療服務為核心，旗下綜合醫院及專科醫院共計11家，擁有獨一味膠囊等36個品種藥品以及中國馳名商標「獨一味」。本案作為最先適用2022年深圳證券交易所等監管機構對上市公司破產重整等事項最新監管規則的重整案件之一，在法律合規方面面臨更多的挑戰。此外，本案還涉及在重整程序中上市公司基金份額回購條款的履行、外商投資准入等諸多複雜法律問題，該等問題與重整程序的進程關係密切，監管機構及社會各方關注度較高。
Hengkang is mainly engaged in providing medical services. It runs 11 general and specialized hospitals and owns 36 varieties of drugs, including Duyiwei capsules, as well as the well-known Chinese trademark 「Duyiwei」. This deal, one of the first reorganizations to which the latest regulatory rules for listed companies promulgated by the Shenzhen Stock Exchange and other regulators in 2022 are applied, has encountered more challenges than ever in legal compliance across the board. In addition, the deal involves many complex legal issues, such as the performance of a clause regarding repurchase of shares in a fund in the reorganization of a listed company, and access of foreign investment, which had a direct bearing on the progress of the reorganization and drew great attention from both regulatory authorities and the general public.
中倫為投資人提供包括重整投資人競任、重整投資協議及重整計劃議定、投後經營方案設計等重整投資全流程法律服務，協助投資人成功實現其投資目標。本次重整有效化解了恆康醫療債務問題，實現了投資人與債權人、債務人的共贏。
To help investors achieve their investment goals, Zhong Lun provided legal services throughout the entire reorganization, including supporting their bid to be eligible reorganization investors, negotiating the reorganization investment agreement and reorganization plan, and designing post-investment operation plans. The reorganization has effectively resolved Hengkang’s debts and achieved a win-win outcome for investors, creditors and debtors.
本項目由合伙人王冰擔任負責人，項目組成員包括合伙人劉濤、律師王崇林、蒲俊霖及曾紫鈺、利爾川等。
The Zhong Lun team for this deal was led by partner Bing WANG and supported by partner Tao LIU and associates Chonglin WANG, Junlin PU, Ziyu ZENG, Erchuan Li, etc.
合伙人簡介
王冰 律師
北京辦公室 合伙人
業務領域：破產清算和重整, 訴訟仲裁
長按識別圖中二維碼，可查閱該合伙人簡歷詳情。
劉濤 律師
北京辦公室合伙人
業務領域：中國內地資本市場, 香港和境外資本市場, 投資併購和公司治理
長按識別圖中二維碼，可查閱該合伙人簡歷詳情。
點擊「閱讀原文」，可查閱該業績新聞官網版。
留言列表